[go: up one dir, main page]

WO2008067928A1 - Compositions absorbant les uv, contenant une pyrrolyltriazine - Google Patents

Compositions absorbant les uv, contenant une pyrrolyltriazine Download PDF

Info

Publication number
WO2008067928A1
WO2008067928A1 PCT/EP2007/010247 EP2007010247W WO2008067928A1 WO 2008067928 A1 WO2008067928 A1 WO 2008067928A1 EP 2007010247 W EP2007010247 W EP 2007010247W WO 2008067928 A1 WO2008067928 A1 WO 2008067928A1
Authority
WO
WIPO (PCT)
Prior art keywords
bis
triazine
radical
benzyl
pyrrol
Prior art date
Application number
PCT/EP2007/010247
Other languages
English (en)
Inventor
Carlos Ramon Trullas Cabanas
Oscar Jimenez Alonso
Jordi Corbera Arjona
David Panyella Costa
Olga Gorchs Capa
Original Assignee
Isdin S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isdin S.A. filed Critical Isdin S.A.
Publication of WO2008067928A1 publication Critical patent/WO2008067928A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4966—Triazines or their condensed derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions

Definitions

  • the present invention refers to a combination of at least 2 UV-absorbing active substances (A) and (B) 1 wherein the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I)
  • UV-absorbing active substance (B) which is defined as hereinafter and which has its absorption maximum ⁇ max in the range of UV-A or UV-B radiation, in combination with at least one UV-absorbing active substance (B), which has its absorption maximum ⁇ m ax(B) in the range of UV-A or UV-B radiation, preferably in such UV radiation range in which the ⁇ max (A) of UV-absorbing active substance (A) does not lie, and wherein the ratio of the molar extinction coefficient at ⁇ max [ ⁇ max(A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at ⁇ max [ ⁇ maX (B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , to a pharmaceutical or a cosmetical composition comprising said combination, to the use of a combination of said active substances for the production of a medicament for the prophylaxis of diseases caused by and/or associated with exposure to ultraviolet radiation and the to use of a combination of active substances for protecting the skin
  • UV radiation is part of the electromagnetic spectrum emitted by the sun.
  • UV-C radiation wavelength [ ⁇ ] range of 100-290 nm; ⁇ 1O o- 29 o
  • UV-A range of 320-400 nm ⁇ 32 o-4oo
  • UVB radiation range of 290-320 nm ⁇ 2 go-32o
  • UV radiation are essential for the production of vitamin D in mammals, especially in human beings, yet overexposure may result in acute and chronic health effects of the skin, eye and/or the immune system.
  • human beings have developed various natural protection systems either to absorb or to deflect said radiation, like the production of melanin, a fatty layer on the skin, and/or the growth of hair.
  • UV-absorbing substances have been developed in order to prevent and/or reduce the effects of solar radiation.
  • Such UV-absorbing substances are compounds that are applied to the skin, lips, nails and/or hair of mammals, especially human beings, in form of additives in cosmetic, dermatological and pharmaceutical formulations. They can also be used as components in polymer compositions, as a component of textile fibers to prevent decomposition of components sensitive to UV radiation or as a further sun protection by means of clothes comprising such fibers.
  • sunscreens which provide at least a high effectiveness either in the UV-A or the UV-B radiation range, preferably in both ranges, since the sunlight radiation intensity, and in consequence the UV radiation, has been increasing continuously.
  • a sufficient protection against such increased UV radiation in order to reduce the risk of suffering of diseases such as skin cancer, polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing and/or chronic actinic dermatitis caused by UV-A and/or UV-B radiation.
  • the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I)
  • an improved sun protection system is obtained for either UV-A or UV-B radiation, or, preferably a complementary UV-absorbing system for absorbing UV-A and UV-B radiation to a considerable extent is obtained.
  • inventive combination allows for an effective absorption of UV radiation either in the UV-A, the UV-B or in both UV-A and UV-B radiation ranges at a remarkable absorption level, i.e. it absorbs UV radiation from either 320 to 400nm, 290 to 320 nm or 290 to 400 nm at least in such amount that an adequate protection for the skin is provided.
  • the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I)
  • n 0, 1 , 2, 3 or 4, preferably 1 , 2, 3 or 4;
  • R 1 represents a hydrogen atom; a linear or branched, unsubstituted or at least monosubstituted Ci- 3 alkyl radical; or a R 2 R 3 substituted phenyl- radical;
  • R 2 , R 2 , R 3 and R 3 independent of each other, each represents a hydrogen atom; a halogen atom; a hydroxy (-OH) residue; an unsubstituted or at least monosubstituted C- ⁇ - 3 alkyl radical; an unsubstituted or at least monosubstituted -O-Ci- 3 radical; or an unsubstituted or at least monosubstituted aryl radical;
  • R 2 and R 3 form together with the phenyl ring to which they are attached, an unsubstituted or at least mono-substituted naphthalene ring;
  • R 4 and R 5 independent of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted C ⁇ alkyl radical; or an unsubstituted or at least mono-substituted aryl radical;
  • a 1 represents a radical of general formula (II), (III) or (IV)
  • a ⁇ 2 represents a radical of general formula (II) or (V)
  • R 6 represents a hydrogen atom; a linear or branched, unsubstituted or at least monosubstituted Ci- 6 alkyl radical; or a hydroxy (-OH) residue;
  • R 16 , R 17 , R 18 , R 19 and R 20 independently of each other, each represents an unsubstituted or at least mono-substituted C 1-6 alkyl radical; an unsubstituted or at least mono-substituted -0-C 1-S radical; an unsubstituted or at least mono-substituted aryl radical; or an -Q-Si(R 21 ) 3 radical;
  • R 21 represents an unsubstituted or at least mono-substituted Ci -6 alkyl radical; an -O- Ci- 6 radical; an unsubstituted or at least mono-substituted aryl radical;
  • R 11 , R 12 and R 13 independently of each other, each represents a hydrogen atom; a linear or branched, unsubstituted or at least monosubstituted Ci-i 8 alkyl radical; an unsubstituted or at least mono-substituted C 3-6 cycloalkyl radical;
  • R 12 and R 13 form together with the bridging nitrogen atom an unsubstituted or at least mono-substituted, saturated 5 to 7-membered cycloaliphatic radical, which contains 1 , 2 or 3 heteroatom(s) as ring member(s) independently selected from the group consisting of O, N and S;
  • R 14 represents an unsubstituted or at least mono-substituted C- M8 alkyl radical; or an unsubstituted or at least mono-substituted aryl radical;
  • R 15 represents an unsubstituted or at least mono-substituted C M S alkyl radical
  • M represents H, Na + or K + ;
  • R 6 and R 7 form together with the phenyl ring an unsubstituted or at least mono- substituted 9 to 15-membered polycyclic ring system;
  • R 6 and R 14 form together with the phenyl ring an unsubstituted or at least mono- substituted 9 to 15-membered polycyclic ring system;
  • the ratio of the molar extinction coefficient at ⁇ max [ ⁇ max (A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at ⁇ ma ⁇ [ ⁇ max (B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably 4:10 to 7:1 ;
  • the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I) as defined above,
  • a 1 and A 2 independent of each other, each represents a radical of general formula (II) or (V)
  • R 6 , R 7 , R 8 and R 9 have the meaning as defined above;
  • the ratio of the molar extinction coefficient at ⁇ max [ ⁇ ma ⁇ (A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at ⁇ max [ ⁇ max(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably 4:10 to 7:1.
  • the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (IA)
  • n 0, 1 , 2, 3 or 4, preferably 1 , 2, 3 or 4;
  • R >1 1 , D R2 , D R3 , D R4 , D R5 , D R8 and R a have the meaning as defined above; and/or is at least one pyrrolyltriazine compound of general formula (IB),
  • n 0, 1 , 2, 3 or 4, preferably 1 , 2, 3 or 4;
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the meaning as defined above;
  • the ratio of the molar extinction coefficient at ⁇ max [ ⁇ m a ⁇ (A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at ⁇ max [ ⁇ max(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably 4:10 to 7:1.
  • the UV- absorbing active substance (A) is at least one pyrrolyltriazine compound of general formulae (I), (IA) or (IB) as defined above,
  • a 1 and A 2 independent of each other, each represents a radical selected from the group consisting of
  • the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of general formulae (I), (IA) or (IB) as defined above,
  • R 1 represents a hydrogen atom; a methyl, ethyl, iso-propyl, n-propyl, benzyl or phenyl radical which is unsubstituted or at least mono-substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I; methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, tert-butyl; -0-CH 3 , -O-C 2 H 5 , -0-CH 2 -CH 2 - CH 3 and phenyl; or a phenyl radical which is in each case substituted with 1 or 2 substituent(s) independently selected from the group consisting of H; methyl, ethyl, iso-propyl, n-propyl and phenyl;
  • R 2 and R 3 independent of each other, each represents a hydrogen atom; methyl, ethyl, iso-propyl, n-propyl or phenyl;
  • R 2 and R 3 form together with the phenyl ring a naphthalene ring which is unsubstituted or at least mono-substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I; methyl, ethyl, iso- propyl, n-propyl, iso-butyl, n-butyl, tert-butyl; -O-CH 3 , -0-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 and phenyl;
  • R 4 and R 5 independent of each other, each represents a hydrogen atom; methyl, ethyl, iso-propyl, n-propyl or phenyl;
  • R 6 represents a a hydrogen atom; -OH; methyl, ethyl, iso-propyl, n-propyl or phenyl;
  • R 16 , R 17 , R 18 , R 19 and R 20 independently of each other, each represents methyl, ethyl, iso-propyl, n-propyl, butyl; -O-CH 3 , -0-C 2 H 5 , -0-CH 2 -CH 2 -CH 3 ; or phenyl;
  • R 11 , R 12 and R 13 independent of each other, each represents methyl, ethyl, iso- propyl, n-propyl, tert-butyl, n-butyl, iso-butyl, pentyl, hexyl or 2-ethylhexyl;
  • R 14 represents methyl, ethyl, iso-propyl, n-propyl, tert-butyl, n-butyl, iso-butyl; or phenyl;
  • active substance (A) has its absorption maximum ⁇ maX (A) in the range of either UV-A or UV-B radiation
  • the ratio of the molar extinction coefficient at ⁇ ma ⁇ [ ⁇ max(A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at ⁇ max [ ⁇ max(B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , preferably 4:10 to 7:1.
  • an active substance (A) is at least one pyrrolyltriazine compound selected from the group consisting of
  • the ratio of the molar extinction coefficient at ⁇ max [ ⁇ ⁇ maX (A)] of the UV- absorbing active substance (A) to the molar extinction coefficient at ⁇ max [ ⁇ max(B)] of the UV-absorbing active substance (B) is from 1:10 to 20:1 , preferably 4:10 to 7:1.
  • the ratio of the molar extinction coefficient at ⁇ max [ ⁇ ⁇ ma ⁇ (A)] of the UV-absorbing active substance (A) to the molar extinction coefficient at ⁇ max [ ⁇ ⁇ m a X (B)] of the UV-absorbing active substance (B) is from 1 :10 to 20:1 , more preferably from 4:10 to 7:1 , most preferably from 2:8 to 8:1.
  • the absorption maximum ⁇ max according to the present invention is defined as the wavelength, at which an UV-absorbing active substance has its absorption maximum.
  • the relevant wavelength range in which the inventive combination absorbs is preferably in the range of UV-A and/or UV-B radiation, i.e. from 290 to 400 nm.
  • the UV-absorbing active substance (A) should have at least one ⁇ max(A) in either the UV-A or UV-B range, preferably with the proviso defined above, and regardless of any additional absorption capacity in the UV radiation range, wherein the ⁇ maX ( A ) does not lie.
  • the absorption maxima Am 3x (A) and ⁇ maX(B) respectively, at least differ in 10 nm, more preferably in at least 20 nm and most preferably in at least 40 nm to each other.
  • the absorption maximum ⁇ max(B) of UV-absorbing active substance (B) is preferably ⁇ 300 nm [ ⁇ ma x (B) ⁇ 300 nm] or > 320 nm [ ⁇ max(B) >320 nm].
  • absorption means any of the following means of reducing the exposure to UV radiation like absorbing, extincting, filtering, scattering, deflecting or reflecting of radiation, since absorption only means the ratio of transmitted radiation to the incident radiation, without determining the mechanism according to which the radiation is reduced.
  • the molar extinction coefficient ( ⁇ ) of a substance is usually measured in solution and can be calculated by the following equation (E 1 ),
  • the molar extinction coefficient ⁇ ⁇ ma ⁇ (A) of the UV-absorbing active substance (A) according to the present invention defines the molar extinction coefficient at the absorption maximum ⁇ max of UV-absorbing active substance (A).
  • the molar extinction coefficient ⁇ ⁇ ma x( B ) of the UV-absorbing active substance (B) according to the present invention defines the molar extinction coefficient at the absorption maximum ⁇ max of UV-absorbing active substance (B).
  • the UV-absorbing active substance (B) has its absorption maximum ⁇ max ( B ) in the range of 290 to 400 nm, with the proviso as defined above, and the UV-absorbing active substance (B) is preferably at least one organic and/or at least one inorganic compound known in the art.
  • the UV-absorbing active substance (B) is at least one compound selected from the group comprising substituted acrylic acid derivatives, allantoin derivatives, aminobenzoic acid derivatives, aminobenzamides derivatives, anthranilic acid derivatives, benzalmalonic acid derivatives, benzimidazole derivatives, benzoic acid derivatives, benzophenone derivatives, benzothiazole derivatives, benzotriazole derivatives, benzoxazole derivatives, camphor derivatives, cinnamic acid derivatives, coumarinic acid derivatives, curcumin derivatives, dianisoylmethane derivatives, dibenzalazine derivatives, dibenzoylmethane derivatives, dioxane derivatives, fungi extract, ferulic acid derivatives, furane derivatives, glutamic acid derivatives, imidazoline derivatives, metal oxides, metal dioxides, nicotinic acid derivatives, nitrobenzamides derivatives, nitrobenzoic acid derivatives,
  • UV-absorbing active substance (B) has its absorption maximum ⁇ maX (B) in the range of 290 to 400 nm, with the proviso as defined above.
  • this active substance (B) is at least one triazine derivative, this active substance (B) has to be different from a compound, which falls under the definition of compounds of general formulae (I), (IA) and (IB) mentioned before.
  • the aforementioned active substances (B) are known to those skilled in the art and are either obtainable by standard techniques or are commercially available.
  • derivative refers to substances in form of their respective free bases, acids, salts, esters and/or ethers.
  • the combination according to the present invention comprises as UV-absorbing active substance (B) at least one compound of general formula (AA)
  • T 1 and T 2 independent of each other, each represents a Ci- ⁇ alkyl radical which can be unsubstituted or at least mono-substituted with radicals independently selected from the group consisting of Ci -4 alkyl, C 5- ⁇ cycloalkyl and aryl;
  • T 4 represents a hydrogen atom or a C-M alkyl radical
  • T 5 represents -OH or a -0-Ci -4 alkyl radical
  • T 6 , T 7 , T 8 and T 9 independent of each other, each represents a Ci -8 alkyl radical or an -O-Ci -8 alkyl radical;
  • T r14 represents a hydrogen atom or a C-M S alkyl radical
  • T 15 represents a Ci -8 alkyl radical which can be unsubstituted, an at least mono- substituted with a phenyl radical or a radical of general formula (Vl 1 )
  • m 1 O or 1 ;
  • R 16' , R 17' , R 18' , R 19' and R j2*0 u " each represents an unsubstituted or at least mono-substituted Ci -6 alkyl radical; an unsubstituted or at least mono-substituted -O-C 1 - 6 radical; an unsubstituted or at least mono-substituted aryl radical; or an -O-Si(R 21 ) 3 radical with R 21' representing an unsubstituted or at least mono-substituted Ci -6 alkyl radical; an -0-Ci -6 radical; an unsubstituted or at least mono-substituted aryl radical;
  • T 16 represents a Ci -8 alkyl radical, which can be unsubstituted or an at least mono- substituted with a phenyl radical;
  • each of the symbols X, independent of each other represents an oxygen or sulfur atom or a group NT 17
  • each of the symbols Z, independent of each other represents a nitrogen atom or a CH group
  • each of the symbols T 17 , independent of each other represents an -OH group, a halogen atom, a linear or branched C-i- ⁇ alkyl radical optionally containing a silicon atom, or a linear or branched -O-Ci -8 alkyl radical
  • each of the numbers r is independent of each other 0, 1 or 2
  • u represents an integer ranging from 1 to 4 inclusive
  • y is equal to 0 or 1
  • each of the numbers r is independent of each other equal to 0 or 1
  • each of the symbols T 17 independently represents a hydrogen atom or a linear or branched C-i- ⁇ alkyl radical or benzyl group optionally containing a silicon atom;
  • a 1 represents a radical of valency u selected from the following group of formulae:
  • each of the symbols T 18 independent of each other represents a halogen atom or a linear or branched Ci -4 alkyl or -0-Ci -4 alkyl radical, or -OH;
  • T 19 represents a hydrogen atom or a linear or branched Ci -4 alkyl radical;
  • W represents a carbon or a nitrogen atom;
  • c 0, 1 , 2, 3 or 4;
  • the active substance (B) is at least one compound selected from the group comprising 2-ethylhexyl 2-cyano-3,3'- diphenylacrylate, ethyl 2-cyano-3,3'-diphenylacrylate, polymer of N- ⁇ (2 and 4)[(2- oxoborn-3-ylidene)methyl]benzyl ⁇ acrylamide, methyl 4-aminobenzoate, butyl 4- aminobenzoate, 5-methyl-2-(1-methylethyl)-cyclohexyl 2-aminobenzoate, glyceryl aminobenzoate, 2-ethylhexyl-p-dimethylethyl-aminobenzoate, 4-aminobenzamide, homomethyl-N-acetyl-anthranilic acid, menthyl antrhanilate, 2-(1 H-benzimidazol-2- yl)-4-methoxyphenol, 2,2'-bis(benzamide), homomethyl-N-acet
  • R 1x represents a hydrogen atom; an optionally substituted cycloalkyl radical from 3 to 7 carbon atoms; an aryl radical which is unsubstituted or at least mono-substituted with a group selected from aryl, halogen, an -0-Ci -6 radical and a Ci -6 alkyl radical; a -phenyl-C 1-6 alkyl radical; a linear or branched Ci -8 alkyl radical which is unsubstituted or at least mono-substituted with a moiety selected from -SO 3 M, -N(R 4x ) 3 + and a radical of general formula (XX)
  • R 5x , R 6x , R 7x , R 8x and R 9x independently of each other, each represents an unsubstituted or at least mono-substituted Ci- 6 alkyl radical; an -O-C 1 - 6 radical; an unsubstituted or at least mono-substituted aryl radical and an -OSi(R 10x ) 3 radical;
  • R 1Ox represents a Ci- 6 alkyl radical; an -0-C 1-6 radical; or an unsubstituted or at least mono-substituted aryl radical;
  • M represents a hydrogen atom, Na + or K + ;
  • R 4x represents an unsubstituted or at least mono-substituted Ci -6 alkyl radical
  • R 2x and R 3x independently of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted Ci_ 4 alkyl radical; or an unsubstituted or at least mono-substituted aryl radical;
  • a , 1x represents a radical of general formula (X1 ) or (X2)
  • a ⁇ 2x represents a radical of general formula (X1 ), (X3) or (X4)
  • R 11x represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted Ci -6 aliphatic radical; or a hydroxy (-OH) residue;
  • each represents a hydrogen atom; a linear or branched, unsubstituted or at least mono-substituted C-i.-i ⁇ alkyl radical;
  • R 14x represents hydrogen atom; or -SO 3 M, with M being H, Na + or K + ;
  • R 13x and R l13x independently of each other, each represents a hydrogen atom; an unsubstituted or at least monosubstituted radical; a linear or branched C 1 - 18 alkyl radical, which is unsubstituted or at least mono-substituted with at least one hydroxy (-OH) residue, a SO 3 M moiety, a -N(R 4x ) 3 + moiety, wherein M and R 4x have the meaning as defined above, or a radical of general formula (XX) as defined above;
  • the UV- absorbing active substance (A) is at least one pyrrolyltriazine compound selected from the group consisting of
  • the UV- absorbing active substance (A) is at least one pyrrolyltriazine compound selected from the group consisting of - 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4-dihydroxyphenyl)-1 ,3,5-triazine,
  • inorganic UV-absorbing active substance (B) selected from the group comprising cerium oxide, iron oxide, manganese oxide, titanium dioxide, zinc oxide, zinc cerium oxide, zirconium oxide;
  • a particularly preferred embodiment of the present invention is a combination of the UV-absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the group consisting of 2-ethylhexyl 2-cyano-3,3'-diphenylacrylate, ethyl 2-cyano-3,3'-diphenylacrylate, polymer of N- ⁇ (2 and 4)[(2-oxoborn-3-ylidene)methyl]benzyl ⁇ acrylamide, methyl A- aminobenzoate, butyl 4-aminobenzoate, 5-methyl-2-(1-methylethyl)-cyclohexyl 2- aminobenzoate, glyceryl aminobenzoate, 2-ethylhexyl-p-dimethylethyl- aminobenzoate, 4-aminobenzamide, homomethyl-N-acetyl-anthranilic acid, menthyl antrhanilate, 2-(1 H-benzimidazol-2-yl)-4-methoxyphenol, 2,2'-bis(benzimidazole), monosodium salt of 2-2'
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine;
  • Another preferred embodiment of the present invention is a combination of UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine;
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine;
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine;
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine:
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • At least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine; with the exception of the combination of 60.5 - 67.6% by weight of 2-(1-benzyl-1 H- pyrrol-2-yl)-4,6-bis[4-(imidazo[1 ,2-a]pyridin-2-yl)phenylamino]-1 ,3,5-triazine with 32.4 - 39.5% by weight of titanium dioxide, in each case related to the total weight of both UV-absorbing active substances.
  • B UV-absorbing active substance selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine;
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • At least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine.
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine.
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine.
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine.
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • At least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine.
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • At least one UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1 -benzyl-1 H-pyrrol-2-yl)-4,6-bis(2, 4- dihydroxyphenyl)-1 ,3,5-triazine.
  • Another preferred embodiment of the present invention is a combination of the UV- absorbing active substance (A)
  • UV-absorbing active substance (B) selected from the before mentioned groups cited in relation to the combination of 2-(1-benzyl-1 H-pyrrol-2-yl)-4,6-bis(2,4- dihydroxyphenyl)-1 ,3,5-triazine.
  • the compound of general formula (IX) is obtained by Friedel-Crafts acylation of resorcinol with the compound of general formula (VIII) in the presence of a Lewis acid, in particular aluminium chloride, in an inert solvent such as xylene (mixture of isomers) and at a temperature between 60 0 C and 10O 0 C, in accordance with the process described in US patent 5,955,060.
  • a Lewis acid in particular aluminium chloride
  • an inert solvent such as xylene (mixture of isomers)
  • the sterification of the p-hydroxyl groups that leads the compounds of general formula (Xl) to be obtained is carried out by alkylation of the compounds of general formula (IX) with a compound of general formula (X), with R 8 being as defined above, and X being a leaving group such as chloro, bromo, tosyl or mesyl, in the presence of a base, such as sodium hydroxide, cesium carbonate, potassium carbonate, sodium tert-butoxide and potassium tert-butoxide, in an appropriate polar solvent such as 2- methoxyethanol, 2-ethoxyethanol, N-methylpyrrolidone, N.N-dimethylformamide and ethanol, at a temperature that ranges between 80 0 C and 120 0 C.
  • a base such as sodium hydroxide, cesium carbonate, potassium carbonate, sodium tert-butoxide and potassium tert-butoxide
  • an appropriate polar solvent such as 2- methoxyethanol, 2-ethoxyethanol, N-methylpyrrol
  • the trialkylated compounds of general formula (IA) are obtained by alkylation of the compound of general formula (Xl) with a compound of general formula (XII), in which R 9 and X have the meaning as defined above, in the presence of a base, such as potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium tert-butoxide and potassium tert-butoxide, in a polar solvent such as 2- methoxyethanol, 2-ethoxyethanol, N-methylpyrrolidone, N,N-dimethylformamide and ethanol, and at a temperature that ranges between 120 0 C and the boiling temperature of the solvent.
  • a base such as potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium tert-butoxide and potassium tert-butoxide
  • a polar solvent such as 2- methoxyethanol, 2-ethoxyethanol, N-methylpyrrolidone, N,N-dimethylformamide and ethanol
  • the compound of general formula (VIII), prepared as defined above reacts with at least 2 equivalents of aniline of general formula (XIII) 1 with R 6 and R 7 being as defined above, in the presence of a base such as N.N-diisopropylethylamine, potassium carbonate, sodium carbonate, caesium carbonate, sodium hydroxide or potassium hydroxide in a solvent such as dioxane, toluene, xylene (mixture of isomers), N,N-dimethylformamide, N-methylpyrrolidone or acetone, at a temperature that ranges between 0 0 C and the boiling temperature of the solvent, preferably between ambient temperature and the boiling temperature of the solvent, and more preferably between 50°C and the boiling temperature of the solvent.
  • a base such as N.N-diisopropylethylamine, potassium carbonate, sodium carbonate, caesium carbonate, sodium hydroxide or potassium hydroxide
  • a solvent such as dioxane
  • the combination of active substances (A) and (B) according to the present invention has preferably an UV-A/UV-B protection ratio in the range of 0,1 to 1 , more preferably 0,2 to 1 , most preferably 0,3 to 1.
  • the UV-A/UV-B protection ratio defines the performance of a sunscreen in the UV-A radiation range (320-400nm) in relation to its performance in the UV-B radiation range (290-320nm). It is calculated as the ratio between the areas defined by the UV- A and UV-B radiation absorption capacity. Both areas are normalized to the range of wavelength involved. A ratio value of 1 indicates that a sunscreen absorbs comparably in UV-A and UV-B radiation range, but is silent about the absolute absorption capacity of a product. If a sunscreen absorbs poorly in the UV-B range, the UV-A/UV-B ratio may be even higher than 1.
  • Preferred UV-A/UV-B protection ratios for the inventive combination are in the range as mentioned before.
  • the inventive combination absorbs preferably at least 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90 or 95% of the total UV-A and UV-B radiation (290 to 400 nm), more preferably at least 50%, even more preferably at least 70%, most preferably at least 85% of the total UV-A and UV-B radiation range (290 to 400 nm).
  • absorption of the total UV-A and UV-B radiation is a measure for the absorption capacity of the inventive combination and refers to the overall absorption in a radiation range from 290 to 400 nm.
  • the total absorption capacity is given by the area under the absorption curve (AUC) in the UV radiation range from 290 to 400 nm.
  • the inventive combination absorbs not only at least 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90 or 95% of the total UV-A radiation (320 to 400 nm), but also at least 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90 or 95% of the total UV-B radiation (290 to 320 nm).
  • the inventive combination absorbs in both the UV-A and UV-B radiation range, the absorption of the total UV-A and UV-B radiation must not exceed 100%. For example, if the inventive combination absorbs 20% in the UV-A radiation range, the maximal absorption in the UV-B radiation range may be 80%.
  • Another aspect of the present invention is a pharmaceutical composition comprising the combination of UV-absorbing substances (A) and (B) as defined above, and optionally at least one pharmacologically acceptable auxiliary agent, as well as to a cosmetical composition comprising the combination of UV-absorbing substances (A) and (B) as defined above and optionally at least one cosmetical vehicle.
  • the inventive pharmaceutical composition comprising the combination of UV-absorbing substances (A) and (B) as defined above may contain at least one further pharmaceutically active substance.
  • Such further pharmaceutically active substance is preferably suitable for the prophylaxis or the treatment of diseases caused by and/or associated with exposure to UV radiation to the skin of mammals, preferably human beings, so that a better therapeutical effect is achieved.
  • the amount of the UV-absorbing active substance (A) and of the UV-absorbing active substance (B) for the inventive pharmaceutical or cosmetical composition is preferably in each case in the range of 0.01% to 30% per weight, more preferably 0.01% to 20% per weight, most preferably 0.1% to 15% per weight, with respect to the total weight of the composition.
  • the inventive combination may be preferably used in micronized form, wherein the size of the particles is preferably in the range of 0.01 to 4 ⁇ m, more preferably in the range of 0.05 to 2 ⁇ m, most preferably in the range of 0,05 to 1 ⁇ m.
  • auxiliary agents can independent of each other be present in either the inventive pharmaceutical or the inventive cosmetical composition: gelling agents, oils, waxes, thickening agents, hydrophilic or hydrophobic polymers, emulsifying agents, emollients, fatty acids, organic solvents, antioxidants, stabilizers, sequestering agents, acidifying or basifying agents, emulsifiers, emollients, surfactants, film formers, biological additives to enhance performance and/or consumer appeal such as amino acids, proteins, vanilla, aloe extract or bioflavinoids, buffering agents, chelating agents such as ethylenediaminetetra-acetic acid (EDTA) or oxalic acid, colorants, dyes, propellants, antifoaming agents, wetting agents, vitamins, emulsion stabilizers, pH adjusters, thickening agents, fragrances, preservatives, opacifying agents, water and/or alcohols.
  • EDTA ethylenediaminetetra-acetic acid
  • oils for the inventive compositions oils from animal or vegetable sources or synthetic are preferably used. Particularly preferred are oils selected from the group comprising liquid petrolatum, liquid paraffin, volatile and non-volatile silicone oils, isoparaffins, polyalphaolefins, fluorated and perfluorated oils.
  • non-ionic, anionic, cationic and amphiphilic tensides can be used, which are preferably selected from the group comprising polyethylenglycol (PEG) and derivatives thereof, tweens, tritons, spans, polygycerines, polyalkyl glycerides, alkyl sulfonates, aryl sulfonates, alkyl phosphates, derivatives of alkyl-betaine and phosphatidylglycerole.
  • PEG polyethylenglycol
  • Emulsifiers are preferably used in certain formulations of the inventive compositions in amounts effective to provide uniform blending of ingredients of the composition.
  • Useful emulsifiers include anionics such as fatty acid soaps, e.g., potassium stearate, sodium stearate, ammonium stearate, and triethanolamine stearate; polyol fatty acid monoesters containing fatty acid soaps, e.g., glycerol monostearate containing either potassium or sodium salt; sulfuric esters (sodium salts), e.g., sodium lauryl 5 sulfate, and sodium acetyl sulfate; and polyol fatty acid monoesters containing sulfuric esters, e.g., glyceryl monostearate containing sodium lauryl surfate; (ii) cationics chloride such as N(stearoyl colamino formylmethyl) pyridium; N-soya-N-eth
  • Emollients may be used in the formulations of the inventive compositions in such amounts to prevent or relieve dryness.
  • Useful emollients include, without limitation hydrocarbon oils and waxes; silicone oils; triglyceride esters; acetoglyceride esters; ethoxylated glyceride; alkyl esters; alkenyl esters; fatty acids; fatty alcohols; fatty alcohol ethers; etheresters; lanolin and derivatives; polyhydric alcohols (polyols) and polyether derivatives; polyhydric alcohol (polyol) esters; wax esters; beeswax derivatives; vegetable waxes; phospholipids; sterols; and/or amides.
  • Surfactants can be used in certain formulations of the inventive compositions. Suitable surfactants are for example those surfactants generally grouped as cleansing agents, emulsifying agents, foam boosters, hydrotropes, solubilizing agents, suspending agents and non-surfactants, which facilitate the dispersion of solids in liquids.
  • Suitable film formers which are preferably used in the formulations of the inventive compositions should keep the composition smooth and even and are preferably, without limitation, at least one substance selected from the group comprising acrylamide/sodium acrylate copolymer; ammonium acrylates copolymer; Balsam Peru; cellulose gum; ethylene/maleic anhydride copolymer; hydroxyethylcellulose; hydroxypropylcellulose; polyacrylamide; polyethylene; polyvinyl alcohol; pvm/MA copolymer (vinyl methylether/maleic anhydride copolymer); PVP (polyvinylpyrrolidone); maleic anhydride polymer, vinylpyrrolidon/hexadecene copolymer; acryliclacrylate copolymer and the like.
  • pH adjusters may also be used in certain formulations of the inventive compositions. These pH adjusters preferably comprise, but are not limited to ammonium hydroxide, triethanolamine or citric acid.
  • Thickening agents used for the formulations of the inventive compositions preferably are, but are not limited to candelilla, carnauba, and microcrystalline waxes, crosslinked acrylic-acid polymers, carbomer, methylhydroxyethylcellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose. and polyethylene thickeners.
  • Examples of preferred organic solvents for the inventive compositions include lower aliphatic alcohols and polyols.
  • Suitable antioxidants suitable for the inventive compositions are preferably selected from the group comprising ascorbic acid (vitamin C), sodium-L-ascorbate, calcium-L- ascorbate, ascorbyl palmitate, butylhydroxyanisole, butylhydroxytoluene, calcium- disodium-EDTA, isoascorbic acid, lecitine, lactic acid, polyphosphate, tocopherol (vitamin E), like ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, propylgallate, octylgallate, dodecylgallate, sodium-isoascorbate, citric acid, sodium citrate, potassium citrate and tin-ll-chloride.
  • Gelling agents which are preferably used in the formulations of the inventive compositions, can be natural or synthetic polymers. Natural polymers are preferably selected from the group comprising Agar-Agar, alginate, pectin, carbomer, carrageenan, casein, dextrine, gelatine, arabic gum, keratine, locust bean gum, xanthan gum and the like. Preferred synthetic polymers which can be used in the formulations of the inventive compositions are selected from the group comprising acylic acid polymers, polyacryl amides and alkylene oxide polymers.
  • inventive cosmetical composition marketed in Europe the respective components shall be used in amounts which are in compliance with the Council Directives 76/768/EEC and Commission Directive 95/17/EC on the approximation of the laws of the Member States relating to cosmetic products.
  • inventive pharmaceutical or cosmetical composition is preferably adapted at least for a once a day, twice or three, four or five times a day, preferably for twice a day application.
  • the inventive pharmaceutical or cosmetical composition may be formulated in liquid or in semi-solid form, preferably as liquid, fluid, foam, cream, gel, paste, balsam, spray, ointment, lotion, conditioner, tonic, milk, mousse, emulsion, serum, oil, stick, shampoo, jelly, suspension, dispersion, lacquer, paint, elixir, drop or aerosol.
  • inventive pharmaceutical or cosmetical compositions are suitable for protecting the skin of UV radiation, either in the range of UV-A or UV-B or the whole UV-A and UV-B range.
  • a measure for the UV-protecting property of an UV-absorbing composition is the "sun protection factor" (SPF).
  • SPDF standard protection factor
  • the SPF of an UV-absorbing composition determined in vivo is a universal indicator of the efficacy against sunburn - the higher the SPF, the more effective is the protection against UV radiation.
  • the level of sun protection has traditionally been estimated using the sun protection factor or SPF test, which utilises the erythemal response of the skin to ultraviolet (UV) radiation.
  • the SPF is a ratio calculated from the energies required to induce a minimum erythemal response with and without sun product applied to the skin of human volunteers, using ultraviolet radiation usually from an artificial source.
  • the SPF of the inventive pharmaceutical or cosmetical compositions is at least 8, more preferably at least 10, even more preferably at least 15 and most preferably at least 20.
  • the UV-A/UV-B ration of the inventive pharmaceutical or cosmetical compositions can be also determined according to the methods disclosed in the before mentioned publications of Diffey B. respectively Diffey BL.
  • inventive pharmaceutical or cosmetical compositions are particularly suitable for keeping scalp, skin, hair and/or nails in good conditions or for moisturizing the skin, treating dry skin successfully and/or against skin ageing and/or photoageing.
  • inventive combinations are preferably suitable for the prophylaxis of diseases caused by and/or associated with exposure to ultraviolet radiation on the skin, preferably the lips, the face and/or the body of mammals.
  • Skin cancer is an increasingly common condition, in part attributed to increased exposure to ultraviolet radiation.
  • the increased exposure is mainly due to the recent popularity of sun tanning (sun bathing).
  • Lighter-skinned individuals are more vulnerable.
  • BCC basal cell carcinoma
  • SCC squamous cell carcinoma
  • the most dangerous type is malignant melanoma, which can be fatal if not treated early, but forms only a small proportion of all skin cancers.
  • Squamous cell carcinoma is a form of cancer of the carcinoma type that may occur in many different organs, including the skin, mouth, esophagus, lungs, and cervix. It is a malignant tumour of epithelium that shows squamous cell differentiation. Squamous cell carcinomas account for about 20% of non-melanoma skin cancers, (with basal cell carcinomas accounting for about 80%), but are clinically more significant because of their ability to metastasize. Squamous cell carcinoma is usually developed in the epithelial layer of the skin and sometimes in various mucous membranes of the body. This type of cancer can be seen on the skin, lips, inside the mouth, throat or esophagus. This type of cancer is characterized by red, scaly skin that becomes an open sore. One risk factor for squamous cell carcinoma is exposure to sunlight.
  • Basal cell carcinoma is the most common skin cancer. It can be destructive and disfiguring. Risk is increased for individuals with a family history of the disease and a high cumulative exposure to UV light via sunlight or, in the past, carcinogenic chemicals especially arsenic. BCC is much more common in fair skinned individuals with a family history of basal cell cancer and increases in incidence closer to the equator at higher altitude. Most sporadic BCC arise in small numbers on sun- exposed skin of people over age 50, although younger people may also be affected.
  • Polymorphic light eruption is a common rash that occurs as a result of photosensitivity.
  • Polymorphic light eruption generally occurs in adult females aged 20 to 40, although it sometimes affects children and rarely males. It is more common in places where sun exposure is uncommon, such as Northern Europe, where it is said to affect 10% of women holidaying in the Mediterranean. It can be the first sign of lupus erythematosus, but this is not usually the case.
  • the name 'polymorphic', or 'polymorphous' refers to the fact that the rash can take many forms, although in one individual it usually looks the same every time it appears.
  • the commonest variety is crops of 2-5 mm pink or red raised spots occurring on the arms. Other areas may be involved, particularly the chest and lower legs, but the face is usually spared.
  • Actinic keratosis is one type of skin cancer, which appears as rough, red or brown, scaly patches on the skin. It is a precancerous condition and develops sometimes into squamous cell cancer.
  • Solar urticaria is the development of hives minutes after exposure to the sun, which resolve in less than 1 hour. Tan skin that has been previously exposed may not react. Solar urticaria is divided into 6 different types depending on the wavelength of light involved.
  • Xeroderma pigmentosum is a genetic disorder of DNA repair in which the body's normal ability to remove damage caused by ultraviolet (UV) light is deficient. This leads to multiple basaliomas and other skin malignancies at a young age. In severe cases, it is necessary to avoid sunlight.
  • UV ultraviolet
  • Skin ageing is a normal process of life but one that many individuals do not take gracefully. With increasing age, cellular cohesion is reduced, renewal time is slower and the elastic tissue degenerates resulting in wrinkles and sagging. Degenerative changes in elastic tissue begin at about 30. The rate of age related changes is influenced by heredity, personal hygiene practices, nutrition, general health and history of sun, radiation and chemical exposure. During the ageing process, cellular cohesion is reduced, the renewal time of the cell layer slows, the moisture content is diminished. The elastic tissues is degraded by enzymes. Photoageing is characterised by chronic inflammation, elastosis.
  • CAD chronic actinic dermatitis
  • PD/AR photosensitivity dermatitis/actinic reticuloid syndrome
  • a sunburn is a burn to the skin produced by overexposure to ultraviolet (UV) radiation, commonly from the sun's rays.
  • UV radiation commonly from the sun's rays.
  • a similar burn can be produced by overexposure to other sources of UV such as from tanning lamps, or occupationally, such as from welding arcs. Exposure of the skin to lesser amounts of UV will often produce a suntan. Usual mild symptoms are red or reddish skin that's hot to the touch, a washed out feeling, and mild dizziness. Sunburn can be life-threatening and is a leading cause of cancer.
  • a further aspect of the present invention relates to the use of the inventive combination mentioned above for the preparation of a pharmaceutical composition for the prophylaxis of diseases caused by and/or associated with exposure to ultraviolet radiation, preferably the lips, the face and/or the body of mammals, preferably human beings, more preferably polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing, chronic actinic dermatitis and/or sunburn.
  • Another preferred aspect is the use of the inventive combination for the preparation of a pharmaceutical composition for the prophylaxis and/or care against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing chronic actinic dermatitis and/or sunburn.
  • Another preferred aspect is the use of the inventive combination for the preparation of a cosmetical composition for the prophylaxis and/or care against non-desired skin conditions comprising polymorphous light eruption, actinic keratosis, solar urticaria, xeroderma pigmentosum, photoageing chronic actinic dermatitis and/or sunburn.
  • another preferred embodiment of the present invention is the use of the inventive combination for the preparation of a cosmetical composition for protecting the skin preferably the lips, the face and/or the body of a mammal, preferably a human, against ultraviolet radiation, preferably UV-A and/or UV-B radiation.
  • An additionally preferred embodiment of the present invention is the use of the inventive combination as described above as a photostabilizer combination additive in polymers and/ or as a component in textile fibers.
  • % by weight of the respective components are related to the total weight of the composition.
  • inventive formulations according to the examples are prepared by standard techniques known by those skilled in the art.
  • a cream formulation with the composition :
  • a cream formulation with the composition :
  • G caprylic/capryc triglyceride (Miglyol 812N (Sasol)) 3.0% H) Ci 2 - 15 alkyl benzoate (Tegosoft TN (Goldschmidt)) 5.0% I) phenoxyethanol (and) methylparaben (and) ethylparaben
  • the UV-A/UV-B ratio of the cream formulation is 0.8 ⁇ 0.02, as determined according to the before mentioned publications of Diffey B. respectively Diffey BL.
  • the SPF of the cream formulation is 9.7 ⁇ 1.2, as determined according to said before mentioned publications.
  • a cream formulation with the composition :
  • Ci 2 - 15 alkyl benzoate (Tegosoft TN (Goldschmidt)) 5.0%
  • a cream formulation with the composition :
  • a cream formulation with the composition :
  • Ci2-1 5 alkyl benzoate (Tegosoft TN (Goldschmidt)) 5.0%
  • a cream formulation with the composition :
  • G caprylic/capryc triglyceride (Miglyol 812N (Sasol)) 3.0% H) Dimethicone (D 200 Fluid 350 CST (Dow Corning)) 0.5% I) phenoxyethanol (and) methylparaben (and) ethylparaben
  • the UV-A/UV-B ratio of the cream formulation is 0.52 ⁇ 0.01 , as determined according to the before mentioned publications of Diffey B. respectively Diffey BL.
  • the SPF of the cream formulation is 27.9 ⁇ 3.5, as determined according to said before mentioned publications.
  • a cream formulation with the composition :
  • the UV-A/UV-B ratio of the cream formulation is 0.42 ⁇ 0.02, as determined according to the publications of Diffey B. respectively Diffey BL.
  • the SPF of the cream formulation is 12.1 ⁇ 1.7, as determined according to said before mentioned publications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention se réfère à une combinaison d'au moins 2 substances actives (A) et (B) absorbant les UV, la substance active (A) absorbant les UV étant au moins un composé pyrrolyltriazine de la formule générale (I), qui est définie ci-après et qui a son maximum d'absorption λmax situé dans la gamme du rayonnement UV-A ou UV-B, en combinaison avec au moins une substance active (B) absorbant les UV, qui a son maximum d'absorption λmax(B) situé dans la gamme du rayonnement UV-A ou UV-B, de préférence dans une gamme de rayonnement UV dans laquelle le λmax(A) de la substance active (A) absorbant les UV ne se situe pas, le rapport du coefficient d'extinction molaire à λmax(A) [eλmax(A)] de la substance active (A) absorbant les UV au coefficient d'extinction molaire à λmax [eλmax(B)] de la substance active (B) absorbant les UV se situant dans l'intervalle allant de 1:10 à 20:1. La présente invention se réfère à une composition pharmaceutique ou cosmétique comprenant ladite combinaison, se réfère à l'utilisation d'une combinaison desdites substances actives pour la production d'un médicament pour la prophylaxie de maladies causées par et/ou associées à l'exposition au rayonnement ultraviolet et l'utilisation d'une combinaison des substances actives pour la protection de la peau des mammifères, comme additif combiné photostabilisant ou comme composant de fibres textiles.
PCT/EP2007/010247 2006-12-04 2007-11-26 Compositions absorbant les uv, contenant une pyrrolyltriazine WO2008067928A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06025059 2006-12-04
EP06025059.4 2006-12-04

Publications (1)

Publication Number Publication Date
WO2008067928A1 true WO2008067928A1 (fr) 2008-06-12

Family

ID=37946487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/010247 WO2008067928A1 (fr) 2006-12-04 2007-11-26 Compositions absorbant les uv, contenant une pyrrolyltriazine

Country Status (4)

Country Link
AR (1) AR064132A1 (fr)
CL (1) CL2007003465A1 (fr)
PE (1) PE20081198A1 (fr)
WO (1) WO2008067928A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051483A1 (fr) 2009-10-30 2011-05-05 Green Molecular, S.L Ptérostilbène (pter) destiné à être utilisé dans la prévention et/ou le traitement des maladies, des atteintes ou des lésions cutanées
EP2409693A3 (fr) * 2010-07-23 2012-02-22 Auriga International Isothiocyanates et dérivés pour l'utilisation dans le traitement et/ou la prévention des lucites
CN102993439A (zh) * 2012-10-30 2013-03-27 无锡三幸高膜科技有限公司 一种水溶性聚三嗪高分子材料
CN107057125A (zh) * 2017-05-18 2017-08-18 句容亿格纳米材料厂 改性水杨酸对正辛基苯基酯的制备及其在抗光污染塑料中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0165608A2 (fr) * 1984-06-22 1985-12-27 Ilford Ag Hydroxyphényltriazines, procédé pour leur préparation et leur utilisation comme absorbant d'UV
WO2003075875A1 (fr) * 2002-03-12 2003-09-18 Ciba Specialty Chemicals Holding Inc. Compositions a absorbeurs d'uv renfermant un compose d'hydroxyphenyltriazine
EP1380583A2 (fr) * 1995-11-23 2004-01-14 Ciba Specialty Chemicals Holding Inc. Bis-résorcinol-triazines et leur utilisation en tant qu'agent antisolaire
WO2004064797A1 (fr) * 2003-01-20 2004-08-05 Ciba Specialty Chemicals Holding, Inc. Derives de la triazine utilises comme absorbants u.v.
WO2006064366A1 (fr) * 2004-12-16 2006-06-22 Isdin, S.A. Derives de 6- (1h-pyrazol-5-yl)-1, 3, 5-triazine et leur utilisation comme agents de protection contre les rayonnements uv

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0165608A2 (fr) * 1984-06-22 1985-12-27 Ilford Ag Hydroxyphényltriazines, procédé pour leur préparation et leur utilisation comme absorbant d'UV
EP1380583A2 (fr) * 1995-11-23 2004-01-14 Ciba Specialty Chemicals Holding Inc. Bis-résorcinol-triazines et leur utilisation en tant qu'agent antisolaire
WO2003075875A1 (fr) * 2002-03-12 2003-09-18 Ciba Specialty Chemicals Holding Inc. Compositions a absorbeurs d'uv renfermant un compose d'hydroxyphenyltriazine
WO2004064797A1 (fr) * 2003-01-20 2004-08-05 Ciba Specialty Chemicals Holding, Inc. Derives de la triazine utilises comme absorbants u.v.
WO2006064366A1 (fr) * 2004-12-16 2006-06-22 Isdin, S.A. Derives de 6- (1h-pyrazol-5-yl)-1, 3, 5-triazine et leur utilisation comme agents de protection contre les rayonnements uv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Löchriger Schutzschrim", STIFTUNG WARENTEST, no. 6, 2004, Berlin, pages 22 - 25, XP002431018 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051483A1 (fr) 2009-10-30 2011-05-05 Green Molecular, S.L Ptérostilbène (pter) destiné à être utilisé dans la prévention et/ou le traitement des maladies, des atteintes ou des lésions cutanées
EP2322159A1 (fr) 2009-10-30 2011-05-18 Green Molecular, S.L. Utilisation de pterostilbene (pter) en tant que médicament pour la prévention et/ou le traitement des maladies de la peau, dommages ou blessures ou en tant que cosmétiques
EP2409693A3 (fr) * 2010-07-23 2012-02-22 Auriga International Isothiocyanates et dérivés pour l'utilisation dans le traitement et/ou la prévention des lucites
CN102993439A (zh) * 2012-10-30 2013-03-27 无锡三幸高膜科技有限公司 一种水溶性聚三嗪高分子材料
CN107057125A (zh) * 2017-05-18 2017-08-18 句容亿格纳米材料厂 改性水杨酸对正辛基苯基酯的制备及其在抗光污染塑料中的应用

Also Published As

Publication number Publication date
PE20081198A1 (es) 2008-09-18
AR064132A1 (es) 2009-03-11
CL2007003465A1 (es) 2009-03-27

Similar Documents

Publication Publication Date Title
US6355230B2 (en) Cosmetic and dermatological light protection formulations with a content of benzotriazole derivatives and alkyl naphthalates
ES2313342T3 (es) Compuestos de benciliden-b-dicarbolino como nuevos absorbentes uv.
KR101737662B1 (ko) Ｕｖ 선 흡수용 2-페닐-1,2,3-벤조트라이아졸
US6803063B2 (en) Photostabilization of dibenzoylmethane derivatives
US20110052516A1 (en) Sunscreens
US20100047185A1 (en) Actvie substance combination
TW202233159A (zh) 用於脂溶性有機日光過濾劑的新穎助溶系統
JP2025065394A (ja) ジエチルアミノヒドロキシベンゾイル安息香酸ヘキシル及び水溶性ｕｖａフィルターを含む効果的な日焼け止め組成物
AU2005229577A1 (en) Use of benzophenone UV filters for preventing tanning
WO2008067928A1 (fr) Compositions absorbant les uv, contenant une pyrrolyltriazine
JP2005206473A (ja) 皮膚外用剤
CN113573690A (zh) 具有二乙氨基羟基苯甲酰基苯甲酸己酯和丁基甲氧基二苯甲酰基甲烷且不含奥克立林的有效防晒组合物
ES2258605T3 (es) Composicion filtrante que contiene al menos un derivado de dibenzoilmetano y el 1,1,3-tri-(2-metil-4-hidroxi-5-terc-butilfenil)-butano.
US20040247540A1 (en) Cosmetic and dermatological light-protective formulation with a content of water-soluble UV-filter substances and alkylnaphthalates
US20090074684A1 (en) Use of alpha olefin copolymers as photostabilizing agents in sunscreen compositions
KR20080080480A (ko) 자외선 차단 화장료
US20040062729A1 (en) Photoprotective sunscreen compositions comprising 1,3,5-triazine compounds and triesters of benenetricarboxylic acids
CN112770716B (zh) 包含甲酚曲唑三硅氧烷以减少织物染色的防晒组合物
US20250195361A1 (en) Compositions containing bis-ethylhexyloxyphenol methoxyphenyl triazine and additional organic uv filter(s)
US20250195374A1 (en) Compositions containing bis-ethylhexyloxyphenol methoxyphenyl triazine and avobenzone
US20250195363A1 (en) Compositions containing bis-ethylhexyloxyphenol methoxyphenyl triazine and additional organic uv filter(s)
US20250195373A1 (en) Compositions containing bis-ethylhexyloxyphenol methoxyphenyl triazine and octinoxate
US20250195381A1 (en) Compositions containing a uv absorbing system including bis-ethylhexyloxyphenol methoxyphenyl triazine and iron oxide
US20250195359A1 (en) Compositions containing bis-ethylhexyloxyphenol methoxyphenyl triazine and titanium dioxide
US20250049667A1 (en) Sunscreen or daily care composition comprising bis-ethylhexyloxyphenol methoxyphenyl triazine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07856263

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07856263

Country of ref document: EP

Kind code of ref document: A1